Nasdaq
$12.28▲ 0.04%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.59BShares out 1.300M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 10.16Pre-market26.10.16 10:29filed6-KKey event#●●●#●●●
MESOBLAST LTDBullish
Mesoblast reported that net revenue for Ryoncil increased by 44% to $28 million in the first fiscal quarter of 2026 compared to the prior year period. Net operating cash spend improved by 85% to $2.3 million, resulting in a strong cash position of $99 million as of September 30, 2026.…more
$12.28+0.04%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15Pre-market26.10.15 20:376-KKey event
MESOBLAST LTD
Mesoblast Limited filed notifications regarding the issuance and cessation of securities (Appendix 2A, 3G, and 3H) with the Australian Securities Exchange (ASX) on October 14, 2026. These filings detail changes to the company's capital structure, including the conversion of unquoted equity securities and new security issuances.…more
$12.28+0.04%vs prev closeView filingShare - 10.13Pre-market26.10.13 19:276-KKey event
MESOBLAST LTD
Mesoblast reported a significant fiscal 2026 revenue of $120.3 million, driven by the successful commercialization of RYONCIL. The company strengthened its balance sheet by establishing a $125 million credit facility, reduced net operating cash utilization to $43.8 million, and ended the year with $102.9 million in cash reserves.…more
$12.28+0.04%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.24Pre-market26.09.24 20:00Bullish#●●●#●●●
Mesoblast Receives FDA Approval for New Potency Assay for Ryoncil
Mesoblast has received FDA approval to implement a new potency assay, TIBA, for the commercial release and quality monitoring of its Ryoncil product. This approval enhances the company's manufacturing quality control and ensures consistent product efficacy.…more
$12.28+0.04%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.27Pre-market26.08.27 22:00
●●●●●●●● ●●●●● ●●●●●●
Mesoblast reported quarterly revenue of $120.25 million, significantly beating analyst estimates, while its EPS of -$0.04 fell short of expectations. Despite the massive year-over-year revenue growth, the continued net loss leads to a neutral outlook.…more
$12.28+0.04%vs prev closeShareBenzinga - 8.27Overnight26.08.27 15:41
●●●●●●●● ●●●●● ●●●●●●
Mesoblast's FY2026 revenue surged to $120.3 million, marking a substantial increase from the previous year. Additionally, the company successfully narrowed its net loss by 44%, signaling improved financial performance.…more
$12.28+0.04%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report